Author: admin

Lupus Nephritis Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Roche, Equillium, BeiGene, Janssen Research & Development, Horizon

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Lupus Nephritis pipeline constitutes 20+ key companies continuously working towards developing 25+ Lupus Nephritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Lupus Nephritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Lupus Nephritis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Lupus Nephritis Market.

 

Some of the key takeaways from the Lupus Nephritis Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Lupus Nephritis treatment therapies with a considerable amount of success over the years. 
  • Lupus Nephritis companies working in the treatment market are Inflection Biosciences, Roche, Equillium, BeiGene, Janssen Research & Development, Horizon Therapeutics, Novartis, Roche, AstraZeneca, Novartis, Alexion Pharmaceuticals, AstraZeneca, Equillium, and others, are developing therapies for the Lupus Nephritis treatment 
  • Emerging Lupus Nephritis therapies in the different phases of clinical trials are- IBL-101, RG 6107, Itolizumab, Zanubrutinib, Guselkumab, Daxdilimab, Secukinumab, Obinutuzumab, GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Ravulizumab, Anifrolumab, Itolizumab, and others are expected to have a significant impact on the Lupus Nephritis market in the coming years.   
  • In July 2023, Kyverna Therapeutics (“Kyverna”), a cell therapy company with the goal of creating a new class of treatments for severe autoimmune diseases, announced today that the Paul-Ehrlich-Institut (PEI) in Germany has approved its first Clinical Trial Application (CTA) for KYV101, a cutting-edge therapy for the treatment of lupus nephritis (LN). In order to treat autoimmune disorders caused by B cells, such as LN, KYV-101 is a unique, totally human anti-CD19 CAR T-cell therapy. It provides a ground-breaking strategy for battling autoimmune diseases by utilising the body’s immune system

 

Lupus Nephritis Overview

One of the most serious organ symptoms of systemic lupus erythematosus (SLE), an autoimmune disease that results in the loss of immunological tolerance to endogenous nuclear material and systemic autoimmunity, is lupus nephritis (LN).

 

Get a Free Sample PDF Report to know more about Lupus Nephritis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight

 

Emerging Lupus Nephritis Drugs Under Different Phases of Clinical Development Include:

  • Secukinumab: Novartis
  • Obinutuzumab: Roche
  • GAZYVA: Roche
  • Saphnelo (Anifrolumab): AstraZeneca
  • Iscalimab: Novartis
  • IBL-101: Inflection Biosciences
  • RG 6107: Roche
  • Itolizumab: Equillium
  • Zanubrutinib: BeiGene
  • Guselkumab: Janssen Research & Development
  • Daxdilimab: Horizon Therapeutics
  • Cosentyx: Novartis
  • Ravulizumab: Alexion Pharmaceuticals
  • Anifrolumab: AstraZeneca

 

Lupus Nephritis Route of Administration

Lupus Nephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Lupus Nephritis Molecule Type

Lupus Nephritis Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Lupus Nephritis Pipeline Therapeutics Assessment

  • Lupus Nephritis Assessment by Product Type
  • Lupus Nephritis By Stage and Product Type
  • Lupus Nephritis Assessment by Route of Administration
  • Lupus Nephritis By Stage and Route of Administration
  • Lupus Nephritis Assessment by Molecule Type
  • Lupus Nephritis by Stage and Molecule Type

 

DelveInsight’s Lupus Nephritis Report covers around 25+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Lupus Nephritis product details are provided in the report. Download the Lupus Nephritis pipeline report to learn more about the emerging Lupus Nephritis therapies

 

Some of the key companies in the Lupus Nephritis Therapeutics Market include:

Key companies developing therapies for Lupus Nephritis are – Novartis, Novartis Pharmaceuticals, Hoffmann-La Roche, Janssen Research & Development, BeiGene, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Alexion Pharmaceuticals, Omeros Corporation, Corestem, Inc., Bristol-Myers Squibb, Boehringer Ingelheim, Apellis Pharmaceuticals, AstraZeneca, Kezar Life Sciences, Equillium, Eledon Pharmaceuticals, Resolve Therapeutics, and others.

 

Lupus Nephritis Pipeline Analysis:

The Lupus Nephritis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Lupus Nephritis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lupus Nephritis Treatment.
  • Lupus Nephritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Lupus Nephritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lupus Nephritis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Lupus Nephritis drugs and therapies

 

Lupus Nephritis Pipeline Market Drivers

  • Increasing Prevalence of Lupus Nephritis, increase in research and developmental activities are some of the important factors that are fueling the Lupus Nephritis Market.

 

Lupus Nephritis Pipeline Market Barriers

  • However, high-cost associated with the disease, lack of awareness among the patients about the disease and other factors are creating obstacles in the Lupus Nephritis Market growth.

 

Scope of Lupus Nephritis Pipeline Drug Insight    

  • Coverage: Global
  • Key Lupus Nephritis Companies: Inflection Biosciences, Roche, Equillium, BeiGene, Janssen Research & Development, Horizon Therapeutics, Novartis, Roche, AstraZeneca, Novartis, Alexion Pharmaceuticals, AstraZeneca, Equillium, and others
  • Key Lupus Nephritis Therapies: IBL-101, RG 6107, Itolizumab, Zanubrutinib, Guselkumab, Daxdilimab, Secukinumab, Obinutuzumab, GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Ravulizumab, Anifrolumab, Itolizumab, and others
  • Lupus Nephritis Therapeutic Assessment: Lupus Nephritis current marketed and Lupus Nephritis emerging therapies
  • Lupus Nephritis Market Dynamics: Lupus Nephritis market drivers and Lupus Nephritis market barriers 

 

Request for Sample PDF Report for Lupus Nephritis Pipeline Assessment and clinical trials

 

Table of Contents 

1. Lupus Nephritis Report Introduction

2. Lupus Nephritis Executive Summary

3. Lupus Nephritis Overview

4. Lupus Nephritis- Analytical Perspective In-depth Commercial Assessment

5. Lupus Nephritis Pipeline Therapeutics

6. Lupus Nephritis Late Stage Products (Phase II/III)

7. Lupus Nephritis Mid Stage Products (Phase II)

8. Lupus Nephritis Early Stage Products (Phase I)

9. Lupus Nephritis Preclinical Stage Products

10. Lupus Nephritis Therapeutics Assessment

11. Lupus Nephritis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Lupus Nephritis Key Companies

14. Lupus Nephritis Key Products

15. Lupus Nephritis Unmet Needs

16 . Lupus Nephritis Market Drivers and Barriers

17. Lupus Nephritis Future Perspectives and Conclusion

18. Lupus Nephritis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lupus Nephritis Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Roche, Equillium, BeiGene, Janssen Research & Development, Horizon

Menkes Disease Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Cyprium Therapeutics and Sentynl Therapeutics, Cyprium Therapeutics

“Menkes Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Menkes Disease, historical and forecasted epidemiology as well as the Menkes Disease market trends in the 7MM.

DelveInsight’s “Menkes Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Menkes Disease, historical and forecasted epidemiology as well as the Menkes Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Menkes Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Menkes Disease Market Forecast

 

Some of the key facts of the Menkes Disease Market Report: 

  • The Menkes Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Menkes syndrome is an inherited X-linked recessive disorder that affects numerous bodily systems, according to the National Organisation for Rare Disorders (NORD), which published this definition in n.d.
  • Menkes Disease was discovered to have 156 diagnosed cases overall in the 7MM in 2021, and it is anticipated that number will rise at a compound annual growth rate (CAGR) of 7.60% during the study period
  • With 79 cases in 2021, or 51% of all confirmed prevalent cases in 7MM, the United States had the most Menkes Disease cases that were diagnosed as being prevalent
  • Menkes Disease was diagnosed in 57 cases in EU4 and the UK in 2021. This number will rise to 84 cases in 2032 at a CAGR of 5.97%
  • Key Menkes Disease Companies: Cyprium Therapeutics and Sentynl Therapeutics, Cyprium Therapeutics, Inc., and others
  • Key Menkes Disease Therapies: CUTX-101, Copper Histidinate, and others
  • The Menkes Disease epidemiology based on gender analyzed that Menkes Disease usually affects male neonates through unaffected carrier women. It may occurs in females, related to unusual genetic circumstances
  • The Menkes Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Menkes Disease pipeline products will significantly revolutionize the Menkes Disease market dynamics.

 

Menkes Disease Overview

Menkes disease (MD) is an X-linked inherited fatal infantile neurodegenerative condition. Mutations in the ATP7A gene, which is in charge of carrying copper throughout the body, result in this inherited X-linked recessive illness.

 

Get a Free sample for the Menkes Disease Market Report: 

https://www.delveinsight.com/report-store/menkes-disease-market

 

Menkes Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Menkes Disease Epidemiology Segmentation:

The Menkes Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Menkes Disease
  • Prevalent Cases of Menkes Disease by severity
  • Gender-specific Prevalence of Menkes Disease
  • Diagnosed Cases of Episodic and Chronic Menkes Disease

 

Download the report to understand which factors are driving Menkes Disease epidemiology trends @ Menkes Disease Epidemiology Forecast

 

Menkes Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Menkes Disease market or expected to get launched during the study period. The analysis covers Menkes Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Menkes Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Menkes Disease Therapies and Key Companies

  • Copper Histidinate: Cyprium Therapeutics, Inc.
  • CUTX-101: Cyprium Therapeutics and Sentynl Therapeutics

 

Menkes Disease Market Drivers

  • Submission of NDA of CUTX-101
  • Increasing awareness among families who have a history of Menkes
  • Parents of affected babies understand the rarity of the disease and allow their children to be a part of the trial
  • Ongoing development of screening techniques
  • Ongoing development of gene therapy

 

Menkes Disease Market Barriers

  • Clinical challenges in the early diagnosis of disease
  • Inability to trace the carrier mother
  • Insufficient number of studies to estimate the exact number of Menkes patients
  • Insufficient number of researches for the treatment of Menkes disease

 

Discover more about therapies set to grab major Menkes Disease market share @ Menkes Disease Treatment Market

 

Scope of the Menkes Disease Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Menkes Disease Companies: Cyprium Therapeutics and Sentynl Therapeutics, Cyprium Therapeutics, Inc., and others
  • Key Menkes Disease Therapies: CUTX-101, Copper Histidinate, and others
  • Menkes Disease Therapeutic Assessment: Menkes Disease current marketed and Menkes Disease emerging therapies
  • Menkes Disease Market Dynamics: Menkes Disease market drivers and Menkes Disease market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Menkes Disease Unmet Needs, KOL’s views, Analyst’s views, Menkes Disease Market Access and Reimbursement 

 

To know more about Menkes Disease companies working in the treatment market, visit @ Menkes Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Menkes Disease Market Report Introduction

2. Executive Summary for Menkes Disease

3. SWOT analysis of Menkes Disease

4. Menkes Disease Patient Share (%) Overview at a Glance

5. Menkes Disease Market Overview at a Glance

6. Menkes Disease Disease Background and Overview

7. Menkes Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Menkes Disease 

9. Menkes Disease Current Treatment and Medical Practices

10. Menkes Disease Unmet Needs

11. Menkes Disease Emerging Therapies

12. Menkes Disease Market Outlook

13. Country-Wise Menkes Disease Market Analysis (2019–2032)

14. Menkes Disease Market Access and Reimbursement of Therapies

15. Menkes Disease Market Drivers

16. Menkes Disease Market Barriers

17.  Menkes Disease Appendix

18. Menkes Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

  

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Menkes Disease Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Cyprium Therapeutics and Sentynl Therapeutics, Cyprium Therapeutics

Diabetic Nephropathy Market Size is anticipated to grow by 2032, estimates DelveInsight

The Diabetic Nephropathy market report provides current treatment practices, emerging drugs, Diabetic Nephropathy market share of the individual therapies, current and forecasted Diabetic Nephropathy market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Diabetic Nephropathy treatment practice/algorithm, market drivers, market barriers and Diabetic Nephropathy unmet needs to curate the best of the opportunities and assesses the underlying potential of the Diabetic Nephropathy market.

 

Key Takeaways from the Diabetic Nephropathy Market Report

  • As per DelveInsight’s analysis, the diabetic nephropathy market size was found to be USD 9.2 billion in 2021 in the 7MM and it is anticipated to grow at a significant CAGR by 2032.
  • As per DelveInsight estimates, the total prevalent population of diabetic nephropathy in 7MM was estimated to be around 28 million cases in 2021 and is expected to increase during the study period (2019–2032).
  • Leading diabetic nephropathy companies such as Prokidney, Inversago Pharma Inc., Palatin Technologies, Inc, Lexicon Pharmaceuticals, Daiichi Sankyo, CSL Behring, and others are developing novel diabetic nephropathy drugs that can be available in the diabetic nephropathy market in the coming years.
  • Some of the key therapies for diabetic nephropathy treatment include Renal Autologous Cell Therapy (REACT), INV-202, Bremelanotide, Ambrisentan and Sotagliflozin, Esaxerenone, CSL346, and others.

 

Discover which therapies are expected to grab the major diabetic nephropathy market share @ Diabetic Nephropathy Market Report

 

Diabetic Nephropathy Overview

Diabetic nephropathy, also known as diabetic kidney disease (DKD), is a chronic kidney condition that develops in individuals with diabetes. This condition arises when elevated blood glucose levels damage the kidneys.

 

Diabetic Nephropathy Epidemiology Segmentation

  • Diabetic Nephropathy Prevalent Cases
  • Diabetic Nephropathy Gender-Specific Cases
  • Diabetic Nephropathy Age-Specific Cases
  • Diabetic Nephropathy Stage-Specific Cases

 

Download the report to understand which factors are driving diabetic nephropathy epidemiology trends @ Diabetic Nephropathy Epidemiological Insights

 

Diabetic Nephropathy Treatment Market 

Diabetic nephropathy presents as a clinical condition characterized by persistent albuminuria and a gradual decline in kidney function, typically associated with a distinctive glomerular disease pattern. Diabetic nephropathy is closely linked to cardiovascular events and significantly impacts overall survival.

 

Learn more about the FDA-approved drugs for diabetic nephropathy @ Drugs for Diabetic Nephropathy Treatment

 

Key Diabetic Nephropathy Therapies and Companies

  • Renal Autologous Cell Therapy (REACT): Prokidney
  • INV-202: Inversago Pharma Inc.
  • Bremelanotide: Palatin Technologies, Inc
  • Ambrisentan and Sotagliflozin: Lexicon Pharmaceuticals
  • Esaxerenone: Daiichi Sankyo
  • CSL346: CSL Behring

 

To know more about diabetic nephropathy clinical trials, visit @ Diabetic Nephropathy Treatment Drugs

 

Diabetic Nephropathy Market Dynamics

The diabetic nephropathy market dynamics are anticipated to change in the coming years. The continuous increase in cases of diabetic nephropathy presents an opportunity for pharmaceutical companies to introduce innovative therapies to the market. Recent advancements in our comprehension of diabetic nephropathy enable the development of new drugs targeting different aspects of the condition, ultimately aiming to halt its progression. 

 

Scope of the Diabetic Nephropathy Market

  • Coverage- 7MM
  • Companies- Prokidney, Inversago Pharma Inc., Palatin Technologies, Inc, Lexicon Pharmaceuticals, Daiichi Sankyo, CSL Behring, and others
  • Therapies- Renal Autologous Cell Therapy (REACT), INV-202, Bremelanotide, Ambrisentan and Sotagliflozin, Esaxerenone, CSL346, and others.
  • Diabetic Nephropathy Unmet Needs, KOL’s views, Analyst’s views, Diabetic Nephropathy Market Access and Reimbursement

 

Discover more about diabetic nephropathy drugs in development @ Diabetic Nephropathy Clinical Trials

 

Table of Content

1. Key Insights

2. Executive Summary of Diabetic Nephropathy

3. Competitive Intelligence Analysis for Diabetic Nephropathy

4. Diabetic Nephropathy: Market Overview at a Glance

5. Diabetic Nephropathy: Disease Background and Overview

6. Patient Journey

7. Diabetic Nephropathy Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Diabetic Nephropathy Unmet Needs

10. Key Endpoints of Diabetic Nephropathy Treatment

11. Diabetic Nephropathy Marketed Products

12. Diabetic Nephropathy Emerging Therapies

13. Diabetic Nephropathy: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Diabetic Nephropathy

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Nephropathy Market Size is anticipated to grow by 2032, estimates DelveInsight

Leptomeningeal Metastases Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | NanoLiposome Plus Therapeutics, AstraZeneca, TYK Medicine

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Leptomeningeal Metastases pipeline constitutes key companies continuously working towards developing Leptomeningeal Metastases treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Leptomeningeal Metastases Pipeline report provides a thorough evaluation of both the commercial and clinical aspects of pipeline products, spanning from the pre-clinical development stage to the marketed phase. It includes a comprehensive description of each drug, encompassing its mechanism of action, clinical studies, any approvals through New Drug Applications (NDAs), and various product development activities. These activities involve technological advancements, collaborations, mergers and acquisitions, funding details, designations, and other pertinent information related to the product.

 

“Leptomeningeal Metastases Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Leptomeningeal Metastases Market.

 

Some of the key takeaways from the Leptomeningeal Metastases Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Leptomeningeal Metastases treatment therapies with a considerable amount of success over the years. 
  • Leptomeningeal Metastases companies working in the treatment market are NanoLiposome Plus Therapeutics, AstraZeneca, TYK Medicine, Angiochem, and others, are developing therapies for the Leptomeningeal Metastases treatment 
  • Emerging Leptomeningeal Metastases therapies in the different phases of clinical trials are- Rhenium-186, AZD1390, TY-9591, ANG1005, and others are expected to have a significant impact on the Leptomeningeal Metastases market in the coming years.   
  • In December 2023, Angiochem is set to initiate a Randomized Open-Label, Multi-Center Pivotal Study named ANGLeD in patients with HER2-Negative Breast Cancer who have newly diagnosed Leptomeningeal Carcinomatosis and have previously undergone treatment for Brain Metastases. This study will compare the efficacy of ANG1005 with the physician’s best choice.

 

Leptomeningeal Metastases Overview

Leptomeningeal carcinomatosis (LC), commonly referred to as “leptomeningeal metastases” or “carcinomatosis meningitis,” is a condition in which the brain’s pia and arachnoid mater, as well as the subarachnoid space in between, are affected by cancer. It was initially described in the late 19th century, and numerous research have been done since on the topic.

 

Get a Free Sample PDF Report to know more about Leptomeningeal Metastases Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/report-store/leptomeningeal-metastases-pipeline-insight

 

Emerging Leptomeningeal Metastases Drugs Under Different Phases of Clinical Development Include:

  • AZD1390: AstraZeneca
  • TY-9591: TYK Medicine
  • Rhenium-186: NanoLiposome Plus Therapeutics
  • ANG1005: Angiochem

 

Leptomeningeal Metastases Pipeline Therapeutics Assessment

  • Leptomeningeal Metastases Assessment by Product Type
  • Leptomeningeal Metastases By Stage and Product Type
  • Leptomeningeal Metastases Assessment by Route of Administration
  • Leptomeningeal Metastases By Stage and Route of Administration
  • Leptomeningeal Metastases Assessment by Molecule Type
  • Leptomeningeal Metastases by Stage and Molecule Type

 

DelveInsight’s Leptomeningeal Metastases Report covers around products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Leptomeningeal Metastases product details are provided in the report. Download the Leptomeningeal Metastases pipeline report to learn more about the emerging Leptomeningeal Metastases therapies

 

Some of the key companies in the Leptomeningeal Metastases Therapeutics Market include:

Key companies developing therapies for Leptomeningeal Metastases are – AstraZeneca, Angiochem., Plus Therapeutics, Y-mAbs Therapeutics, and others.

 

Leptomeningeal Metastases Pipeline Analysis:

The Leptomeningeal Metastases pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Leptomeningeal Metastases with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Leptomeningeal Metastases Treatment.
  • Leptomeningeal Metastases key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Leptomeningeal Metastases Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Leptomeningeal Metastases market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Leptomeningeal Metastases drugs and therapies

 

Leptomeningeal Metastases Pipeline Market Drivers

  • Increasing Prevalence of Leptomeningeal Metastasess, increase in research and developmental activities are some of the important factors that are fueling the Leptomeningeal Metastases Market.

 

Leptomeningeal Metastases Pipeline Market Barriers

  • However, high-cost associated with the disease, side-effects associated with the treatment and other factors are creating obstacles in the Leptomeningeal Metastases Market growth.

 

Scope of Leptomeningeal Metastases Pipeline Drug Insight    

  • Coverage: Global
  • Key Leptomeningeal Metastases Companies: NanoLiposome Plus Therapeutics, AstraZeneca, TYK Medicine, Angiochem, and others
  • Key Leptomeningeal Metastases Therapies: Rhenium-186, AZD1390, TY-9591, ANG1005, and others
  • Leptomeningeal Metastases Therapeutic Assessment: Leptomeningeal Metastases current marketed and Leptomeningeal Metastases emerging therapies
  • Leptomeningeal Metastases Market Dynamics: Leptomeningeal Metastases market drivers and Leptomeningeal Metastases market barriers 

 

Request for Sample PDF Report for Leptomeningeal Metastases Pipeline Assessment and clinical trials

 

Table of Contents 

1. Leptomeningeal Metastases Report Introduction

2. Leptomeningeal Metastases Executive Summary

3. Leptomeningeal Metastases Overview

4. Leptomeningeal Metastases- Analytical Perspective In-depth Commercial Assessment

5. Leptomeningeal Metastases Pipeline Therapeutics

6. Leptomeningeal Metastases Late Stage Products (Phase II/III)

7. Leptomeningeal Metastases Mid Stage Products (Phase II)

8. Leptomeningeal Metastases Early Stage Products (Phase I)

9. Leptomeningeal Metastases Preclinical Stage Products

10. Leptomeningeal Metastases Therapeutics Assessment

11. Leptomeningeal Metastases Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Leptomeningeal Metastases Key Companies

14. Leptomeningeal Metastases Key Products

15. Leptomeningeal Metastases Unmet Needs

16 . Leptomeningeal Metastases Market Drivers and Barriers

17. Leptomeningeal Metastases Future Perspectives and Conclusion

18. Leptomeningeal Metastases Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Leptomeningeal Metastases Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | NanoLiposome Plus Therapeutics, AstraZeneca, TYK Medicine

Tank Trailers Market Size, Growth & Statistics Report from 2024 to 2030

“Tank Trailers Market”
The global tank trailers market size is anticipated to register a significant CAGR of around 5% during the forecast period from 2024 to 2030.

The projected period from 2024 to 2030 anticipates a notable growth, with an expected significant Compound Annual Growth Rate (CAGR) of around 5% in the global tank trailers market. The increasing demands in the chemical and petrochemical sectors propel the need for specialized trailers, and the upswing in oil and gas exploration activities underscores the necessity for efficient crude oil transportation. Various industries, including agriculture, construction, and manufacturing, contribute to the demand for tank trailers for the transportation of liquid and dry bulk materials. Stringent safety regulations and compliance standards further accentuate the requirement for specialized trailers, highlighting the pivotal role of regulatory frameworks. The expansion of the food and beverage industry adds an additional layer, necessitating trailers to adhere to stringent sanitary standards.

To know more about this study, request a free sample report @ https://www.rcmarketanalytics.com/request-sample/?id=854

Market Trends:

  • Technological Advancements: Ongoing technological advancements in the design and manufacturing of tank trailers are a key trend. Innovations in materials, structural integrity, and safety features contribute to increased efficiency, reliability, and compliance with industry standards.
  • Environmental Sustainability: The tank trailers market is witnessing a trend towards environmental sustainability. Manufacturers and operators are increasingly focusing on developing and adopting eco-friendly materials, energy-efficient designs, and technologies to reduce the environmental impact of transportation.
  • Specialized Trailers for Niche Industries: Growing demand for specialized tank trailers tailored to the unique needs of various industries such as chemicals, petrochemicals, food and beverages, and pharmaceuticals is a notable trend. Customized trailers designed for specific cargo types or industry requirements are gaining popularity.
  • Digitalization and Connectivity: Integration of digital technologies, telematics, and connectivity features in tank trailers is on the rise. Real-time monitoring, tracking, and data analytics help enhance operational efficiency, safety, and maintenance planning for fleet operators.
  • Safety Regulations and Compliance: Increasing emphasis on safety regulations and compliance standards is a persistent trend. Stringent rules regarding the transportation of hazardous materials and the need for advanced safety features in tank trailers are influencing design and manufacturing practices.

According to the recent report published by RC Market Analytics, the Global Tank Trailers Market is expected to provide sustainable growth opportunities during the forecast period from 2023 to 2030. This latest industry research study analyzes the tank trailers market by various product segments, applications, regions and countries while assessing regional performances of numerous leading market participants. The report offers a holistic view of the tank trailers industry encompassing numerous stakeholders including raw material suppliers, providers, distributors, consumers and government agencies, among others. Furthermore, the report includes detailed quantitative and qualitative analysis of the global market considering market history, product development, regional dynamics, competitive landscape, and key success factors (KSFs) in the industry.

Browse the Full Report Discretion @ https://www.rcmarketanalytics.com/tank-trailers-market/

Geographically, the tank trailers market report comprises dedicated sections centering on the regional market revenue and trends. The tank trailers market has been segmented on the basis of geographic regions into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Tank trailers market estimates have also been provided for the historical years 2020 & 2021 along with forecast for the period from 2023 – 2030.The report includes a deep-dive analysis of key countries including the U.S., Canada, the U.K., Germany, France, Italy, China, Japan, India, Australia, Mexico, Brazil and South Africa, among others. Thereby, the report identifies unique growth opportunities across the world based on trends occurring in various developed and developing economies.

The Tank Trailers Market Segmentation:

By Material:

  • Stainless Steel
  • Aluminum
  • Carbon Steel

By Product Type:

  • Liquid
  • Dry Bulk

By Capacity:

  • Small Tank (below 5,000 gallons)
  • Medium Tank (5,000 to 10,000 gallons)
  • Large Tank (over 10,000 gallons)

By End-Use Industry:

  • Chemical
  • Oil & Gas
  • Food and Beverage
  • Others

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Key participants in the worldwide tank trailers market include Wabash National Corporation, Polar Tank Trailer, LLC, Heil Trailer International, MAC Trailer Manufacturing, and Brenner Tank, LLC. These companies are employing strategies such as expansion, new investments, the introduction of innovative services, and collaboration to navigate markets effectively. In their pursuit of a competitive edge, players are actively expanding into new geographical areas through both organic growth and strategic acquisitions, leveraging joint synergies to strengthen their market positions.

To know more about this study, request a free sample report @ https://www.rcmarketanalytics.com/request-sample/?id=854

Key Questions Answered by Tank Trailers Market Report:

  • Product popularity and adoption based on various country-level dynamics
  • Regional presence and product development for leading market participants
  • Market forecasts and trend analysis based on ongoing investments and economic growth in key countries
  • Competitive landscape based on revenue, product offerings, years of presence, number of employees and market concentration, among others
  • Various industry models such as SWOT analysis, Pestle Analysis, Porter’s Five Force model, Value Chain Analysis pertaining to Tank Trailers market
  • Analysis of the key factors driving and restraining the growth of the global, regional and country-level markets from 2020-2030

About Us: RC Market Analytics is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to aid businesses identify market opportunities to optimize strategies. Our expert’s team of analysts’ provides enterprises with strategic insights. RC Market Analytics works to help enterprises grow through strategic insights and actionable solutions. Feel free to contact us for any report customization at sales@researchcorridor.com.

Media Contact
Company Name: RC Market Analytics Pvt. Ltd.
Contact Person: Vijendra Singh
Email: Send Email
Country: India
Website: https://www.researchcorridor.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Tank Trailers Market Size, Growth & Statistics Report from 2024 to 2030

The Global Spinal Surgery Devices Market is expected to grow at a significant CAGR of 5.65% from 2023 to 2028

As a result, the spinal surgery devices market is poised for substantial growth in the coming years. Some of the leading players in the market include Medtronic, Johnson & Johnson, Stryker, NuVasive, Zimmer Biomet, Globus Medical, Inc., Alphatec Spine, Inc., Orthofix Holdings, Inc., RTI Surgical Holdings, Ulrich GmbH & Co. KG, B. Braun Melsungen AG, Seaspine Holdings Corporation, and others.

 

DelveInsight’s “Spinal Surgery Devices Market Insight, Competitive Landscape, and Market Forecast 2028” research report provides the current and forecasted Spinal Surgery Devices market size, share, and trends analysis for the next five years. Moreover, it highlights the ongoing innovations in the segment, major market drivers & barriers, key competitors, and emerging devices in the domain.

 

Spinal Surgery Devices Market: Overview

Spinal surgery devices are medical instruments and equipment used during surgical procedures on the spine to treat various spinal conditions and disorders. These devices are essential tools that help surgeons access the spine, stabilize it, correct deformities, and promote healing. 

 

Types of Spinal Surgery Devices:

  • Implants: These are permanent devices placed within the spine to provide stability, such as spinal fusion implants, interbody cages, and pedicle screws.
  • Navigation Systems: These advanced technologies assist surgeons in planning and executing precise spinal procedures by providing real-time imaging and guidance.
  • Surgical Instruments: These include a wide range of tools like retractors, drills, and microscopes, which help surgeons access and work on the spine effectively.
  • Biologics: These are substances like bone grafts or synthetic materials used to promote bone growth and fusion during spinal surgery.
  • Orthopedic Hardware: Devices like plates and rods are used to stabilize the spine and correct deformities in conditions like scoliosis.

 

Spinal surgery devices find critical applications across a spectrum of spinal conditions and disorders, revolutionizing the treatment landscape. One primary application lies in herniated disc repair, where these devices enable surgeons to remove or repair damaged discs with precision, alleviating pain and restoring spinal functionality. Additionally, spinal surgery devices play a pivotal role in spinal fusion procedures, utilizing implants and bone grafts to stabilize the spine and promote fusion, particularly in cases of degenerative disc disease.

 

Furthermore, these devices are instrumental in the correction of conditions like scoliosis, offering orthopedic hardware that aids in realigning and stabilizing the spine to correct abnormal curvature. Patients with vertebral fractures, often linked to osteoporosis, benefit from spinal surgery devices as they provide stability to fractured vertebrae, reducing pain and enhancing mobility. For those facing the challenge of spinal tumors, navigation systems, and precision instruments facilitate tumor removal while preserving vital healthy tissue. Lastly, spinal surgery devices help alleviate symptoms in individuals with spinal stenosis by creating more space in the spinal canal, relieving pressure on nerves, and improving their quality of life. In essence, these devices are indispensable in the diagnosis and treatment of a wide range of spinal conditions, enhancing patient outcomes and overall quality of life.

 

To provide a better understanding of the market dynamics, DelveInsight’s “Spinal Surgery Devices Market” report provides a detailed assessment by product type (thoracic fusion and lumbar fusion devices [posterior and interbody]), (cervical fusion devices [anterior, and posterior]), spine biologics, vertebral compression fracture treatment devices, spinal decompression devices, spinal bone stimulators), non-fusion devices ([dynamic stabilization devices, artificial discs, annulus repair discs, and nuclear disc prosthesis]), by technology (spinal fusion & fixation, vertebral compression fracture treatment, spinal decompression, motion preservation), by surgery type (open surgery and minimally invasive surgery), and end-user (hospitals, specialty clinics, and ambulatory surgical centers).

 

In the spinal surgery devices market, the posterior lumbar fusion devices segment is poised for significant revenue growth. This is attributed to the increasing availability of advanced products, a surge in product launches and approvals, and the numerous benefits associated with posterior lumbar fusion devices. These devices offer technological advantages like improved mechanical stability, optimized sagittal parameters, and enhanced fusion potential. Moreover, they provide a minimally invasive approach that requires only two small incisions, potentially reducing the need for disrupting back muscles. Additionally, these devices are known for their ability to minimize blood loss and post-surgical incisional pain, making them a preferred choice in the market.

 

Spinal Surgery Devices Market Analysis

A prominent driving force behind the growth of the spinal surgery devices market is the escalating incidence of permanent or temporary disabilities, primarily attributable to the surging rate of road accidents resulting in spinal cord injuries. Additionally, the market is further propelled by the increasing frequency of workplace injuries, contributing to the expanding landscape of spinal surgery device applications. This uptrend underscores the critical role these devices play in addressing the consequences of traumatic events and occupational hazards, reinforcing their significance in healthcare and patient rehabilitation.

 

The growing acceptance of minimally invasive medical interventions, particularly laser-based spinal surgery procedures, is fueling the demand for technologically advanced laser spinal surgery devices. This trend not only underscores the current market dynamics but also presents promising opportunities for the future expansion of this segment. As patients and healthcare providers increasingly prioritize less invasive treatment options, the development and deployment of innovative laser spinal surgery devices become essential, ensuring improved patient outcomes, shorter recovery times, and enhanced overall surgical experiences. Consequently, the evolving landscape of minimally invasive techniques stands as a significant catalyst for the growth and evolution of laser spinal surgery devices in the healthcare domain.

 

Moreover, the consistent stream of new product introductions by prominent market players is exerting a substantial positive impact on the expansion of the spinal surgery devices sector. These ongoing efforts to innovate and bring cutting-edge solutions to the market not only reflect the industry’s commitment to advancement but also contribute significantly to meeting the evolving needs of healthcare professionals and patients alike. These new offerings, driven by technological advancements and refined design, enhance the overall quality of spinal surgeries, offering improved precision, safety, and outcomes. As such, the frequent launch of novel products emerges as a key driver in propelling the growth trajectory of the spinal surgery devices market.

 

Hence, the aforementioned factors, when taken into account collectively, are poised to exert a substantial influence on the trajectory of the global spinal surgery devices market over the forecast period spanning from 2023 to 2028. As innovation, technological advancements, and a growing need for effective spinal solutions continue to shape the healthcare landscape, the spinal surgery devices market stands as a dynamic and pivotal component in addressing these evolving demands.

 

Nevertheless, several challenges may hamper the growth of the spinal surgery devices market. Notably, the elevated cost associated with spinal surgery procedures and the devices used therein could present barriers to access and affordability for some patients and healthcare systems. Additionally, the potential adverse effects linked to spinal surgery devices must be vigilantly monitored and managed to ensure patient safety and satisfaction. 

 

Interested to know more about the ongoing developments in the market? Visit to get an in-depth insight @ Spinal Surgery Devices Types and Emerging Products

 

 

Global Spinal Surgery Devices Market Assessment and Forecast

Out of all the geographical regions, North America is poised to assert its dominance in the global spinal surgery devices market to maintain the leading position throughout the forecast period spanning from 2023 to 2028. This sustained dominance is attributed to several factors. North America boasts advanced healthcare infrastructure, a high prevalence of spinal disorders, and a robust presence of key market players actively engaged in research, development, and innovation within the field of spinal surgery devices. Moreover, the region’s proactive adoption of cutting-edge medical technologies continues to drive growth and reinforces its pivotal role in shaping the global landscape of spinal surgery device utilization.

 

Europe and the Asia-Pacific region are emerging as promising growth hubs for the global spinal surgery devices market. Several factors contribute to their future potential in this sector. In Europe, supportive government policies, including streamlined approval processes for new products and favorable reimbursement policies in various countries, are creating an environment conducive to market growth. Similarly, select Asian nations are experiencing these advantages, propelling the adoption of spinal surgery devices.

 

Furthermore, the availability of a diverse range of options within the market is boosting popularity and adoption rates in both regions. Patients and healthcare providers have access to a variety of advanced solutions, enhancing the overall quality of spinal surgical procedures. Additionally, the prevalence of spinal diseases in Europe is on the rise, making it one of the leading chronic health challenges. This surge in spinal conditions is driving the demand for spinal surgery devices as healthcare systems seek effective treatments and interventions to address this growing health concern. These collective factors underscore the potential growth and significance of Europe and the Asia-Pacific region in shaping the global landscape of spinal surgery device utilization.

 

Interested in knowing how the market will grow by 2028? Click to get a snapshot @ Spinal Surgery Devices Market Trends and Developments

 

Key Developments and Breakthroughs in Spinal Surgery Devices Market

Over the years, the Spinal Surgery Devices market has evolved significantly, owing to the active participation of the global MedTech companies and technological advancements in the domain. Similarly, several clinical, commercial, and regulatory developments have also been registered in the domain. Some of the major advancements in the Spinal Surgery Devices market in recent years include –

  • On October 3, 2023, Amber Implants, an innovative medical technology company developing next-generation implants for spinal injuries, announced the official start of the clinical trials for the VCFix Spinal System. This first-in-human clinical trial will assess the safety and effectiveness of the VCFix implant for patients suffering from vertebral compression fractures without bone cement. The implant is provided with a user-friendly, single-use sterile surgical kit, ensuring perfect traceability and reducing the risk of infection.

 

Learn more about major clinical and commercial development in the market @ Spinal Surgery Devices Market Clinical and Commercial Development Activities

 

Key Companies in the Spinal Surgery Devices Market

Globally, some of the leading MedTech giants working in the Spinal Surgery Devices market include Medtronic, Johnson & Johnson, Stryker, NuVasive, Zimmer Biomet, Globus Medical, Inc., Alphatec Spine, Inc., Orthofix Holdings, Inc., RTI Surgical Holdings, Ulrich GmbH & Co. KG, B. Braun Melsungen AG, Seaspine Holdings Corporation, and others. Due to increasing demand and favorable revenue generation prospects, several new entrants are expected to join the market, resulting in heightened competitiveness within the sector.

 

Learn how new players’ entries will transform the market dynamics in the coming years @ Spinal Surgery Device’s Competitive Landscape

 

Scope of the Spinal Surgery Devices Market Report:

  • Study Period – 2020-2028
  • Geography Covered – North America, Europe, Asia-Pacific, and Rest of the World
  • Spinal Surgery Devices Market Assessment 
  • By Product Type – Thoracic Fusion and Lumbar Fusion Devices (Posterior And Interbody), Cervical Fusion Devices (Anterior, and Posterior), Spine Biologics, Vertebral Compression Fracture Treatment Devices, Spinal Decompression Devices, Spinal Bone Stimulators), Non-Fusion Devices (Dynamic Stabilization Devices, Artificial Discs, Annulus Repair Discs, and Nuclear Disc Prosthesis)
  • By Technology – Spinal Fusion & Fixation, Vertebral Compression Fracture Treatment, Spinal Decompression, Motion Preservation
  • By Surgery Type – Open Surgery and Minimally Invasive Surgery
  • By End-User – Hospitals, Specialty Clinics, And Ambulatory Surgical Centers
  • Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s Views

 

Table of Content

1. Spinal surgery Devices Market Report Introduction

2. Spinal surgery Devices Market Executive Summary

3. Regulatory Analysis

4. Spinal surgery Devices Market Key Factors Analysis

5. Spinal surgery Devices Market Porter’s Five Forces Analysis

6. COVID-19 Impact Analysis on Spinal surgery Devices Market

7. Spinal surgery Devices Market Layout

8. Spinal surgery Devices Market Company and Product Profiles

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

 

Reach out to us to get a more detailed overview of the market and the key offerings of the report @ Spinal Surgery Devices Market Insights and Competitive Landscape

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Global Spinal Surgery Devices Market is expected to grow at a significant CAGR of 5.65% from 2023 to 2028

The Herpes Zoster Market is expected to strengthen as awareness of the disease increases and more effective interventions are being developed.

The Herpes Zoster market report provides current treatment practices, emerging drugs, Herpes Zoster market share of the individual therapies, current and forecasted Herpes Zoster market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Herpes Zoster treatment market, market drivers, market barriers and Herpes Zoster unmet needs to curate the best of the opportunities and assesses the underlying potential of the Herpes Zoster market.

 

Key Takeaways from the Herpes Zoster Market Report

  • As per DelveInsight analysis, the herpes zoster market size in the 7MM was found to be USD 834 million in 2022 and it is expected to grow positively at a significant CAGR during the study period (2019–2032).
  • According to DelveInsight’s estimates, in 2022, the number of healthy patient population at-risk for herpes zoster in the United States was found to be more than 100 million which is expected to increase to more than 160 million by 2032.
  • Leading herpes zoster companies such as Immorna Biotherapeutics, Inc., ICON plc, Zhuhai Trinomab Pharmaceutical Co., Ltd., Curevo Inc, Green Cross Corporation, ModernaTX, Inc., Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, and others are developing novel herpes zoster drugs that can be available in the herpes zoster market in the coming years.
  • Some key therapies for herpes zoster treatment include JCXH-105, TNM005, CRV-101 Vaccine Antigen High Dose, mRNA-1468, PF-07915234, HZ/su vaccine, Herpes Zoster Vaccine GSK1437173A, Varicella Zoster Vaccine, and others.

 

Discover which therapies are expected to grab the major herpes zoster market share @ Herpes Zoster Market Report

 

Herpes Zoster Overview

Herpes zoster, commonly known as shingles, is a neurocutaneous condition primarily triggered by the reactivation of the varicella-zoster virus (VZV). This reactivation typically arises from a latent VZV infection in the dorsal sensory or cranial nerve ganglia following an initial VZV infection earlier in life. Once reactivated, the virus migrates along a nerve pathway to the skin, resulting in the development of a characteristic rash.

 

Herpes Zoster Epidemiology Segmentation

  • Total Healthy Patient Population at-risk for Herpes Zoster
  • Eligible Patient Population for Herpes Zoster Vaccination

 

Herpes Zoster Treatment Market

Shingles treatment should commence within three days of the rash appearing, and it’s typically initiated by a dermatologist or another healthcare professional. Starting treatment early, within this timeframe, can help prevent potential complications, such as persistent nerve pain. The primary treatment options for shingles, according to the National Foundation for Infectious Diseases, include antiviral medications and vaccines. For vaccines, Zostavax and Shingrix are available choices.

 

To know more about herpes zoster treatment, visit @ Herpes Zoster Treatment Drugs

 

Key Herpes Zoster Therapies and Companies

  • JCXH-105: Immorna Biotherapeutics, Inc./ICON plc
  • TNM005: Zhuhai Trinomab Pharmaceutical Co., Ltd.
  • CRV-101 Vaccine Antigen High Dose: Curevo Inc/Green Cross Corporation
  • mRNA-1468: ModernaTX, Inc.
  • PF-07915234: Pfizer
  • HZ/su vaccine: GlaxoSmithKline
  • Herpes Zoster Vaccine GSK1437173A: GlaxoSmithKline
  • Varicella Zoster Vaccine: Bristol-Myers Squibb

 

Herpes Zoster Market Dynamics

The herpes zoster market dynamics have undergone significant changes over the years. Firstly, the aging population is a significant driver. As the global population continues to age, the risk of developing herpes zoster increases, creating a growing patient pool for antiviral medications and vaccines. Additionally, advancements in medical research and development have brought new treatments and vaccines to the market. Vaccination campaigns, such as the introduction of the varicella-zoster vaccine, have helped reduce the incidence and severity of herpes zoster. This, in turn, affects the demand for antiviral medications and preventive treatments.

 

Learn more about the FDA-approved drugs for herpes zoster @ Drugs for Herpes Zoster Treatment

 

Scope of the Herpes Zoster Market

  • Coverage- 7MM
  • Companies- Immorna Biotherapeutics, Inc., ICON plc, Zhuhai Trinomab Pharmaceutical Co., Ltd., Curevo Inc, Green Cross Corporation, ModernaTX, Inc., Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, and others
  • Therapies- JCXH-105, TNM005, CRV-101 Vaccine Antigen High Dose, mRNA-1468, PF-07915234, HZ/su vaccine, Herpes Zoster Vaccine GSK1437173A, Varicella Zoster Vaccine, and others
  • Herpes Zoster Unmet Needs, KOL’s views, Analyst’s views, Herpes Zoster Market Access and Reimbursement

 

Discover more about herpes zoster drugs in development @ Herpes Zoster Clinical Trials

 

Table of Content

1. Key Insights

2. Herpes Zoster Executive Summary

3. Herpes Zoster Competitive Intelligence Analysis

4. Herpes Zoster Market Overview at a Glance

5. Herpes Zoster Market Disease Background and Overview

6. Patient Journey

7. Herpes Zoster Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Herpes Zoster Unmet Needs

10. Key Endpoints of Herpes Zoster Treatment

11. Herpes Zoster Marketed Products

12. Herpes Zoster Emerging Therapies

13. Herpes Zoster: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Herpes Zoster Market Outlook

16. Herpes Zoster Market Access and Reimbursement Overview

17. KOL Views

18. Herpes Zoster Market Drivers

19. Herpes Zoster Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Herpes Zoster Market is expected to strengthen as awareness of the disease increases and more effective interventions are being developed.

SiC Substrates Market Size, Growth & Statistics Report from 2024 to 2030

“SiC Substrates Market”
The global SiC (Silicon Carbide) substrates market size is projected to grow at a higher CAGR of over 19% during the forecast period from 2024 to 2030.

The forecasted period from 2024 to 2030 anticipates a substantial growth, with a projected higher Compound Annual Growth Rate (CAGR) exceeding 19% in the global Silicon Carbide (SiC) substrates market. The escalating demand for power electronics, particularly in sectors such as electric vehicles, renewable energy, and power supply units, underscores the critical role SiC substrates play. Recognized for their superior electrical properties, these substrates offer distinct advantages over traditional silicon, making them indispensable in applications requiring high-frequency operation and resistance to elevated temperatures. The automotive industry’s transition to electric vehicles further emphasizes the significance of SiC substrates, enhancing efficiency in powertrains and charging systems. Additionally, SiC substrates play a crucial role in the renewable energy sector, optimizing energy conversion in applications related to solar and wind power.

To know more about this study, request a free sample report @ https://www.rcmarketanalytics.com/request-sample/?id=863

Market Trends:

Growing Demand:

  • Rise of electric vehicles (EVs): EVs require efficient power electronics, which benefit from SiC’s high-temperature and high-power capabilities. This is driving significant demand for SiC substrates in EV charging stations, inverters, and on-board electronics.
  • Renewable energy: SiC substrates are crucial for efficient power conversion in solar, wind, and other renewable energy systems.
  • Industrial applications: SiC’s ability to handle harsh environments and high temperatures makes it ideal for industrial applications like motor drives, power supplies, and welding equipment.

Technological Advancements:

  • Larger wafer sizes: Increasing the diameter of SiC wafers reduces production costs and enables fabrication of more complex devices.
  • Improved crystal growth techniques: Advancements in techniques like Physical Vapor Deposition (PVD) are leading to higher quality and larger SiC substrates.
  • Epitaxial layer optimization: Developments in epitaxial layer growth are enhancing device performance and efficiency.

According to the recent report published by RC Market Analytics, the Global SiC Substrates Market is expected to provide sustainable growth opportunities during the forecast period from 2023 to 2030. This latest industry research study analyzes the SiC substrates market by various product segments, applications, regions and countries while assessing regional performances of numerous leading market participants. The report offers a holistic view of the SiC substrates industry encompassing numerous stakeholders including raw material suppliers, providers, distributors, consumers and government agencies, among others. Furthermore, the report includes detailed quantitative and qualitative analysis of the global market considering market history, product development, regional dynamics, competitive landscape, and key success factors (KSFs) in the industry.

Browse the Full Report Discretion @ https://www.rcmarketanalytics.com/sic-substrates-market/

Geographically, the SiC substrates market report comprises dedicated sections centering on the regional market revenue and trends. The SiC substrates market has been segmented on the basis of geographic regions into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. SiC substrates market estimates have also been provided for the historical years 2020 & 2021 along with forecast for the period from 2023 – 2030.The report includes a deep-dive analysis of key countries including the U.S., Canada, the U.K., Germany, France, Italy, China, Japan, India, Australia, Mexico, Brazil and South Africa, among others. Thereby, the report identifies unique growth opportunities across the world based on trends occurring in various developed and developing economies.

The SiC Substrates Market Segmentation:

By Wafer Diameter:

  • 2-Inch
  • 4-Inch
  • 6-Inch and Above

By Application:

  • Power Devices
  • RF Devices
  • LEDs
  • Others

By End-Use Industry:

  • Electronics & Semiconductors
  • Automotive
  • Aerospace & Defense
  • Energy & Power
  • Others

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Key participants in the worldwide SiC substrates market include Wolfspeed Inc., II-VI Incorporated, STMicroelectronics, SK Siltron Inc., and Xiamen Powerway Advanced Material Co. Ltd. These companies are employing strategies such as expansion, fresh investments, service innovation, and collaboration to explore and expand their market presence. In pursuit of a competitive edge, players are actively expanding into new regions through both organic growth and strategic acquisitions, leveraging joint synergies to strengthen their market positions.

To know more about this study, request a free sample report @ https://www.rcmarketanalytics.com/request-sample/?id=863

Key Questions Answered by SiC Substrates Market Report:

  • Product popularity and adoption based on various country-level dynamics
  • Regional presence and product development for leading market participants
  • Market forecasts and trend analysis based on ongoing investments and economic growth in key countries
  • Competitive landscape based on revenue, product offerings, years of presence, number of employees and market concentration, among others
  • Various industry models such as SWOT analysis, Pestle Analysis, Porter’s Five Force model, Value Chain Analysis pertaining to SiC Substrates market
  • Analysis of the key factors driving and restraining the growth of the global, regional and country-level markets from 2020-2030

About Us: RC Market Analytics is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to aid businesses identify market opportunities to optimize strategies. Our expert’s team of analysts’ provides enterprises with strategic insights. RC Market Analytics works to help enterprises grow through strategic insights and actionable solutions. Feel free to contact us for any report customization at sales@researchcorridor.com.

Media Contact
Company Name: RC Market Analytics Pvt. Ltd.
Contact Person: Vijendra Singh
Email: Send Email
Country: India
Website: https://www.researchcorridor.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: SiC Substrates Market Size, Growth & Statistics Report from 2024 to 2030

Automotive Traction Control Systems Market Size, Growth & Statistics Report to 2030

“Automotive Traction Control Systems Market”
The global automotive traction control systems market size is anticipated to grow at a significant CAGR of around 6% during the forecast period from 2024 to 2030.

The projected period from 2024 to 2030 foresees a substantial growth, with an estimated noteworthy Compound Annual Growth Rate (CAGR) of approximately 6% in the global automotive traction control systems market. Stringent safety regulations on a global scale are compelling automakers to integrate traction control systems, ensuring both vehicle stability and compliance with safety standards. The continual expansion of global vehicle production, especially in emerging markets, is driving the demand for these systems as standard features in contemporary vehicles. Consumer preferences for advanced safety features are contributing to the increasing adoption of traction control systems, enhancing vehicle stability during acceleration, braking, and cornering. Ongoing technological advancements in sensors and electronic control units (ECUs) are further improving the reliability and performance of these systems.

Market Trends:

  • Rising demand for safety features: Consumers are increasingly prioritizing safety features like traction control when making car purchase decisions, creating a favorable market environment for these systems.
  • Focus on cost reduction: Manufacturers are investing in research and development to optimize production processes and reduce the cost of traction control systems, making them more affordable for a wider range of vehicles.
  • Growing competition: The market is witnessing increasing competition among established players and new entrants, leading to innovation and a wider variety of traction control systems available.
  • Integration with telematics: Connectivity features are being incorporated into traction control systems, allowing for remote monitoring and data analysis for improved performance and predictive maintenance.
  • Increased demand in emerging markets: Growing economies in regions like Asia Pacific and Latin America are expected to see a significant rise in demand for traction control systems due to rising disposable incomes and increased focus on vehicle safety.

According to the recent report published by RC Market Analytics, the Global Automotive Traction Control Systems Market is expected to provide sustainable growth opportunities during the forecast period from 2023 to 2030. This latest industry research study analyzes the automotive traction control systems market by various product segments, applications, regions and countries while assessing regional performances of numerous leading market participants. The report offers a holistic view of the automotive traction control systems industry encompassing numerous stakeholders including raw material suppliers, providers, distributors, consumers and government agencies, among others. Furthermore, the report includes detailed quantitative and qualitative analysis of the global market considering market history, product development, regional dynamics, competitive landscape, and key success factors (KSFs) in the industry.

Browse the Full Report Discretion @ https://www.rcmarketanalytics.com/automotive-traction-control-systems-market/

Geographically, the automotive traction control systems market report comprises dedicated sections centering on the regional market revenue and trends. The automotive traction control systems market has been segmented on the basis of geographic regions into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Automotive traction control systems market estimates have also been provided for the historical years 2020 & 2021 along with forecast for the period from 2023 – 2030.The report includes a deep-dive analysis of key countries including the U.S., Canada, the U.K., Germany, France, Italy, China, Japan, India, Australia, Mexico, Brazil and South Africa, among others. Thereby, the report identifies unique growth opportunities across the world based on trends occurring in various developed and developing economies.

The Automotive Traction Control Systems Market Segmentation:

By Type:

  • Mechanical System
  • Electric System

By Component:

  • Hydraulic Modulators
  • ECU
  • Sensors
  • Others

By Vehicle Type:

  • Passenger Vehicle
  • Commercial Vehicle

By Sales Channel:

  • OEM
  • Aftermarket

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Key players in the worldwide automotive traction control systems market include Bosch GmbH, Continental AG, ZF Friedrichshafen AG, Denso Corporation, and Aisin Seiki Co., Ltd. These companies are adopting strategies such as expansion, new investments, the introduction of innovative services, and collaboration to navigate markets effectively. In their pursuit of a competitive edge, players are actively expanding into new geographical areas through both organic growth and strategic acquisitions, leveraging joint synergies to strengthen their market positions.

To know more about this study, request a free sample report @ https://www.rcmarketanalytics.com/request-sample/?id=857

Key Questions Answered by Automotive Traction Control Systems Market Report:

  • Product popularity and adoption based on various country-level dynamics
  • Regional presence and product development for leading market participants
  • Market forecasts and trend analysis based on ongoing investments and economic growth in key countries
  • Competitive landscape based on revenue, product offerings, years of presence, number of employees and market concentration, among others
  • Various industry models such as SWOT analysis, Pestle Analysis, Porter’s Five Force model, Value Chain Analysis pertaining to Automotive Traction Control Systems market
  • Analysis of the key factors driving and restraining the growth of the global, regional and country-level markets from 2020-2030

About Us: RC Market Analytics is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to aid businesses identify market opportunities to optimize strategies. Our expert’s team of analysts’ provides enterprises with strategic insights. RC Market Analytics works to help enterprises grow through strategic insights and actionable solutions. Feel free to contact us for any report customization at sales@researchcorridor.com.

Media Contact
Company Name: RC Market Analytics Pvt. Ltd.
Contact Person: Vijendra Singh
Email: Send Email
Country: India
Website: https://www.researchcorridor.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Automotive Traction Control Systems Market Size, Growth & Statistics Report to 2030

Acute Myeloid Leukemia (AML) Market Primed for Unprecedented Growth Throughout Forecast Period (2023-2032) – Delveinsight | Abbvie, Actinium, Agastiya, Celgene, CellCentric, Chimerix, Gilead

“Delveinsight Business Research LLP”
The landscape of the Acute Myeloid Leukemia (AML) Market is poised for a significant evolution in the foreseeable future. This transformation is primarily attributed to the increasing incidence of Acute Myeloid Leukemia cases and the introduction of novel therapies into the market. Additionally, advancements in diagnostic techniques and a deeper understanding of AML’s molecular underpinnings are expected to further shape the trajectory of this market.

DelveInsight’s “Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Acute Myeloid Leukemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Acute Myeloid Leukemia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Acute Myeloid Leukemia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Acute Myeloid Leukemia: An Overview

Acute myeloid leukemia (AML) (also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. AML can involve tissues outside the bone marrow and blood, including lymph nodes, the brain, skin, and other parts of the body.

The most prevalent form of leukemia in adults is AML, which makes up around 80% of all cases. It is characterized by ineffective erythropoiesis and bone marrow failure is caused by clonal growth of immature “blast cells” in the peripheral blood and bone marrow. AML is the most common acute leukemia in adults and primarily affects older people with a median age of diagnosis of ~67 years. The chromosomal anomalies that each patient possesses are often exclusive to them. The frequency of anomalies is greater as people age.

Acute Myeloid Leukemia Market Key Facts

  • AML is one of the most common types of leukemia in adults. Still, AML is fairly rare overall, accounting for only about 1% of all cancers.

  • According to Cancer Research UK, AML incidence is strongly related to age, with the highest incidence rate being in older people. In the UK in 2016-2018, on average each year, more than 4 in 10 new cases (42%) were in people aged 75 and over. Age-specific incidence rates rise gradually from birth, rise steadily from around age 50-54, rise more steeply from age 60-64, and drop in the oldest age groups.

  • As per the study by Miyamoto & Minami (2019), the annual incidence of AML in Japan is 5.6 per 100,000.

  • According to data from a report titled, “Global Burden of Disease Study”, by the Institute for Health Metrics and Evaluation (2018), in 2017, among the EU5 countries, the UK had the highest prevalence of AML, at more than 5,000 cases, while Spain has the lowest at under 2,300 cases.

  • According to the Surveillance, Epidemiology, and End Results (SEER) study program, the rate of new cases of acute myeloid leukemia was 4.3 per 100,000 men and women per year in the United States. 

  • As per DelveInsight’s analysis, acute myeloid leukemia (AML) is more prominent in males in comparison to females.

Acute Myeloid Leukemia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Acute Myeloid Leukemia pipeline therapies. It also thoroughly assesses the Acute Myeloid Leukemia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Acute Myeloid Leukemia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Acute Myeloid Leukemia Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Acute Myeloid Leukemia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Acute Myeloid Leukemia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Acute Myeloid Leukemia Epidemiology, Segmented as –

  • Total Incident Cases of Acute Myeloid Leukemia in the 7MM (2019–2032)

  • Gender-specific Cases of Acute Myeloid Leukemia in the 7MM (2019–2032)

  • Age-specific Cases of Acute Myeloid Leukemia in the 7MM (2019–2032)

  • Mutation-specific Cases of Acute Myeloid Leukemia in the 7MM (2019–2032)

Acute Myeloid Leukemia Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Acute Myeloid Leukemia market or expected to be launched during the study period. The analysis covers the Acute Myeloid Leukemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Acute Myeloid Leukemia drugs based on their sale and market share.

The report also covers the Acute Myeloid Leukemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Acute Myeloid Leukemia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Acute Myeloid Leukemia Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market

Acute Myeloid Leukemia Therapeutics Analysis

The goal of treatment is remission. Current conventional therapeutic options for AML rely on intensive chemotherapy-based induction and consolidation therapy, together with hematopoietic stem cell transplantation. However, not all patients are eligible for intensive therapy, which can be both physically and mentally demanding, and this approach is more frequently used in healthy, younger patients. Since 2017 the US Food and Drug Administration (FDA) has approved glasdegib, venetoclax, ivosidenib, midostaurin, CPX- 351, and gemtuzumab ozogamicin (GO) to treat persons with newly diagnosed acute myeloid leukemia. The European Medicines Agency (EMA) has done likewise for midostaurin, CPX-351, and GO.

Despite the new therapies, there are several limitations associated with the current milieu of drugs. The high relapse rate in the high-risk population remains a major concern. The intensive chemotherapy treatments used for AML have serious

To further improve the treatment scenario, several major pharma and biotech companies are developing Acute Myeloid Leukemia therapies. Currently, Gamida Cell is leading the therapeutics market with its Acute Myeloid Leukaemia drug candidates in the most advanced stage of clinical development.

Acute Myeloid Leukemia Companies Actively Working in the Therapeutics Market Include

Abbvie, Actinium Pharmaceuticals, Agastiya Biotech, AGC Biologics S.p.A., Agios Pharmaceuticals, Allogene therapeutics, Aprea Therapeutics, Aptevo Therapeutics, Armaceutica, Arog Pharmaceuticals, Astellas Pharma, Astex Pharmaceuticals, Inc., AstraZeneca, Bellicum Pharmaceuticals, BerGenBio ASA, Bio-Path Holdings, Biosight Ltd., Bristol-Myers Squibb, Cardiff Oncology, Celgene, CellCentric Ltd., Chimerix, Clear Creek Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Curis, Inc., Daiichi Sankyo., DCPrime BV, Delta-Fly Pharma, Forma Therapeutics, GEMoaB Monoclonals, Gilead Sciences, GlycoMimetics, GlycoMimetics Incorporated, GT Biopharma, Inc., Hanmi Pharmaceutical Company Limited, Immune-Onc Therapeutics, Immunicum, ImmunityBio, ImmunoGen, Inc., Immunomedics, Inc., Incyte Corporation, Janssen Research & Development, LLC, Jasper Therapeutics, Jazz Pharmaceuticals, Kronos Bio, MacroGenics, MediGene, Molecular Partners, New Epsilon Innovation Limited, NexImmune Inc., Novartis, Oncoceutics, Orca Bio, PersonGen BioTherapeutics, Pfizer, Poseida Therapeutics, Precigen, Inc., Rafael Pharmaceuticals Inc., Sellas Life Sciences Group, Sumitomo Dainippon Pharma Co., Ltd., Syndax Pharmaceuticals, Synimmune GmbH, Syros Pharmaceuticals, Takeda Oncology, TC BioPharm, Teva Pharmaceutical Industries, Xencor, Inc., and others.

Emerging and Marketed Acute Myeloid Leukemia Therapies Covered in the Report Include:

  • Omidubicel: Gamida Cell

  • Uproleselan: GlycoMimetics

  • ALT 803: ImmunityBio

  • BPX-501: Bellicum Pharmaceuticals

  • Dociparstat Sodium (Chimerix Pharmaceuticals)

  • Crenolanib besylate: Arog pharmaceuticals

  • JSP191: Jasper Therapeutics

And Many More

The Report Covers an In-depth Assessment of Emerging Drugs and key Companies. Download the Sample Report to Learn More @

https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Acute Myeloid Leukemia Competitive Intelligence Analysis

4. Acute Myeloid Leukemia Market Overview at a Glance

5. Acute Myeloid Leukemia Disease Background and Overview

6. Acute Myeloid Leukemia Patient Journey

7. Acute Myeloid Leukemia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Acute Myeloid Leukemia Treatment Algorithm, Current Treatment, and Medical Practices

9. Acute Myeloid Leukemia Unmet Needs

10. Key Endpoints of Acute Myeloid Leukemia Treatment

11. Acute Myeloid Leukemia Marketed Therapies

12. Acute Myeloid Leukemia Emerging Drugs and Latest Therapeutic Advances

13. Acute Myeloid Leukemia Seven Major Market Analysis

14. Attribute Analysis

15. Acute Myeloid Leukemia Market Outlook (In US, EU5, and Japan)

16. Acute Myeloid Leukemia Companies Active in the Market

17. Acute Myeloid Leukemia Access and Reimbursement Overview

18. KOL Views on the Acute Myeloid Leukemia Market

19. Acute Myeloid Leukemia Market Drivers

20. Acute Myeloid Leukemia Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Marginal Zone Lymphoma Market

“Marginal Zone Lymphoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Marginal Zone Lymphoma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Marginal Zone Lymphoma market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Myeloid Leukemia (AML) Market Primed for Unprecedented Growth Throughout Forecast Period (2023-2032) – Delveinsight | Abbvie, Actinium, Agastiya, Celgene, CellCentric, Chimerix, Gilead